Published on 28 May 2024 on Benzinga
RBC Capital Markets has downgraded Sarepta Therapeutics Inc SRPT as it weighs recent investor feedback, company commentary, and public statements from senior FDA officials.
The analyst reports that after extensive discussions with investors over the past several weeks, expectations for the FDA’s label decision on Elevidys have significantly increased, especially with shares now up 50% in the last six months.